AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15729066 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Endoscopic Surgery Trainer (VEST)
Number of subjects: 32
Study 15729066 — intervention group
Group type: COMPARATOR
Intervention: Conventional Video Trainer (CVT)
Number of subjects: 32
Study 15729066 — intervention group
Group type: COMPARATOR
Intervention: Control task on Day 5
Number of subjects: 32
Study 15729066 — intervention group
Group type: EXPERIMENTAL
Intervention: Experts
Number of subjects: 32
Study 12170856 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-implant overdenture on ball attachments
Number of subjects: 60
Study 12170856 — intervention group
Group type: COMPARATOR
Intervention: Conventional denture
Number of subjects: 60
Study 11158794 — intervention group
Group type: COMPARATOR
Intervention: No treatment (observed without therapy)
Number of subjects: 160
Study 9043967 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (food-based diets)
Number of subjects: 110
Study 8183101 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose polymer-electrolyte beverage (GP; N = 24)
Number of subjects: 48
Study 8183101 — intervention group
Group type: COMPARATOR
Intervention: Tap water (TW; N = 24)
Number of subjects: 48
Study 3654426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice packs applied to the skin of the face, chest, thigh, and upper arm; random sequence; specific conductance measured
Number of subjects: 23
Study 3654426 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation of frigid air
Number of subjects: 23
Study 3654426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing cold air at rest
Number of subjects: 23
Study 3654426 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevating ventilation in a cold environment
Number of subjects: 23
Study 3654426 — intervention group
Group type: COMPARATOR
Intervention: Warm packs applied to the same areas
Number of subjects: 23
Study 29725986 — intervention group
Group type: EXPERIMENTAL
Intervention: Active analgesic treatment (paracetamol or buprenorphine transdermal system)
Number of subjects: 162
Study 29725986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 29725986 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 162
Study 29725986 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 162
Study 29725986 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 162
Study 26103778 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance tocolysis with nifedipine
Number of subjects: 236
Study 26103778 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 236
Study 25802960 — intervention group
Group type: EXPERIMENTAL
Intervention: High Interval Training (HIT) at 85%-95% of heart rate reserve, 3 days a week for 6 weeks
Number of subjects: 28
Study 25802960 — intervention group
Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) at 70%-85% of heart rate reserve, 3 days a week for 6 weeks
Number of subjects: 28
Study 23921272 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Number of subjects: 94
Study 23921272 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 94
Study 20626273 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS‐SN
Number of subjects: 27
Study 20626273 — intervention group
Group type: COMPARATOR
Intervention: CTL‐SN
Number of subjects: 27
Study 19033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 25
Study 19033417 — intervention group
Group type: EXPERIMENTAL
Intervention: IAPP replacement using pramlintide
Number of subjects: 25
Study 19033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-derived glucose appearance in plasma
Number of subjects: 25
Study 19033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic glucose sequestration
Number of subjects: 25
Study 16816307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (n=21)
Number of subjects: 62
Study 16816307 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (n=23)
Number of subjects: 62
Study 16816307 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control (n=18)
Number of subjects: 62
Study 12784590 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg per kg body weight, administered over 3 days)
Number of subjects: 268
Study 10791849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (+) in TS-(+) group
Number of subjects: 148
Study 10791849 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (-) in TS-(+) group
Number of subjects: 148
Study 10791849 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (+) in TS-(‐) group
Number of subjects: 148
Study 10791849 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (-) in TS-(‐) group
Number of subjects: 148
Study 10791849 — intervention group
Group type: EXPERIMENTAL
Intervention: TS-(‐) group
Number of subjects: 148
Study 10791849 — intervention group
Group type: COMPARATOR
Intervention: TS-(+) group
Number of subjects: 148
Study 8651843 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention simulating an informed consent presentation (n = 103)
Number of subjects: 205
Study 8651843 — intervention group
Group type: COMPARATOR
Intervention: Single sentence about the PSA (control group, n = 102)
Number of subjects: 205
Study 1495743 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitonin nasal spray (300 MRC units)
Number of subjects: 0
Study 30856378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 30856378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0
Study 30856378 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and fluoxetine (COMB)
Number of subjects: 0
Study 30856378 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT) vs. Fluoxetine (FLX)
Number of subjects: 0
Study 30856378 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (FLX) vs. Combination of CBT and fluoxetine (COMB)
Number of subjects: 0
Study 30856378 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioural therapy (CBT) vs. Combination of CBT and fluoxetine (COMB)
Number of subjects: 0
Study 29408163 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 60
Study 29408163 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation
Number of subjects: 60
Study 29408163 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 29408163 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 26909789 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental arm (handgrip exercise with blood flow restriction)
Number of subjects: 9
Study 26909789 — intervention group
Group type: COMPARATOR
Intervention: Control arm (handgrip exercise without blood flow restriction)
Number of subjects: 9
Study 26909789 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 9
Study 26909789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 9
Study 24515550 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacist intervention involving medication reconciliation, patient education, and improved communication of the discharge medication plan.
Number of subjects: 592
Study 24515550 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 592
Study 22639800 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 24
Study 22639800 — intervention group
Group type: COMPARATOR
Intervention: Plastic curets + cotton pellets + sterile saline (CPS)
Number of subjects: 24
Study 19654548 — intervention group
Group type: EXPERIMENTAL
Intervention: BMC therapy
Number of subjects: 30
Study 19654548 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 30
Study 17426306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group visits
Number of subjects: 186
Study 17426306 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 186
Study 16361188 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgery (6-24 months)
Number of subjects: 532
Study 16361188 — intervention group
Group type: COMPARATOR
Intervention: Late surgery (32-60 months)
Number of subjects: 532
Study 16361188 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 532
Study 12572637 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing 0.836% sodium monofluorophosphate (1100 ppm F) in a dicalcium phosphate dihydrate base plus 10% xylitol
Number of subjects: 2539
Study 12572637 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice containing 0.836% sodium monofluorophosphate (1100 ppm F) in a dicalcium phosphate dihydrate base
Number of subjects: 2539
Study 9854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 50 mg/kg
Number of subjects: 150
Study 9854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 100 mg/kg
Number of subjects: 150
Study 9854660 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 150 mg/kg
Number of subjects: 150
Study 9854660 — intervention group
Group type: COMPARATOR
Intervention: Control (no tranexamic acid)
Number of subjects: 150
Study 8568017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin with food (medium-fat breakfast)
Number of subjects: 16
Study 8568017 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin without food (fasting)
Number of subjects: 16
Study 2403428 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 81
Study 2403428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 38178 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 113
Study 38178 — intervention group
Group type: COMPARATOR
Intervention: Control (sulfasalazine, prednisone, or placebo)
Number of subjects: 113
Study 30676887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hinting Task (HT) performance
Number of subjects: 132
Study 27796131 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 51
Study 27796131 — intervention group
Group type: COMPARATOR
Intervention: ZDV/sdNVP
Number of subjects: 51
Study 26466809 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention A: continuance of oral intake and regular mouth care
Number of subjects: 12
Study 26466809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention B: continuance of oral intake, regular mouth care and clinically assisted hydration
Number of subjects: 12
Study 23410777 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 61
Study 23410777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 23410777 — intervention group
Group type: COMPARATOR
Intervention: 1 transfusion cycle (fresh-frozen plasma/platelets)
Number of subjects: 61
Study 23410777 — intervention group
Group type: COMPARATOR
Intervention: 2 transfusion cycles (fresh-frozen plasma and platelets)
Number of subjects: 61
Study 21385928 — intervention group
Group type: EXPERIMENTAL
Intervention: sulindac (300 mg daily)
Number of subjects: 189
Study 21385928 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac (400 mg daily)
Number of subjects: 189
Study 21385928 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 189
Study 18977478 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg once daily for 2 months
Number of subjects: 43
Study 18977478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40mg once daily for 2 months
Number of subjects: 43
Study 18977478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 17847756 — intervention group
Group type: EXPERIMENTAL
Intervention: LUNA alone
Number of subjects: 67
Study 17847756 — intervention group
Group type: COMPARATOR
Intervention: LUNA plus PN
Number of subjects: 67
Study 15018257 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patient visits
Number of subjects: 60
Study 15018257 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention survey of pharmacists
Number of subjects: 60
Study 11310931 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 15
Study 11310931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 11310931 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine admixture
Number of subjects: 15
Study 9380241 — intervention group
Group type: EXPERIMENTAL
Intervention: Active-type vitamin D3 (VD) administered to Group 2 (19 patients; 10 males and 9 females)
Number of subjects: 38
Study 9380241 — intervention group
Group type: COMPARATOR
Intervention: No active-type vitamin D3 (VD) administered to Group 1 (19 patients; 15 males and 4 females)
Number of subjects: 38
Study 9380241 — intervention group
Group type: EXPERIMENTAL
Intervention: Class III oxyphilic cell area
Number of subjects: 38
Study 9380241 — intervention group
Group type: EXPERIMENTAL
Intervention: Class I oxyphilic cell area
Number of subjects: 38
Study 9380241 — intervention group
Group type: EXPERIMENTAL
Intervention: All classes of oxyphilic cell area
Number of subjects: 38
Study 9380241 — intervention group
Group type: EXPERIMENTAL
Intervention: HS- and C-PTH levels in the serum
Number of subjects: 38
Study 7700068 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertension therapy
Number of subjects: 0
Study 7700068 — intervention group
Group type: COMPARATOR
Intervention: Event-based trials
Number of subjects: 0
Study 3606369 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook-based program for energy conservation behaviors
Number of subjects: 25
Study 3606369 — intervention group
Group type: COMPARATOR
Intervention: Standard occupational therapy (OT)
Number of subjects: 25
Study 30564950 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete or absent recovery of echocardiographic parameters at 6 months
Number of subjects: 219
Study 27854064 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg
Number of subjects: 0
Study 27854064 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg
Number of subjects: 0
Study 25237132 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 56
Study 25237132 — intervention group
Group type: COMPARATOR
Intervention: Education-only intervention (control)
Number of subjects: 56
Study 23391676 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 80 or 120 mg daily
Number of subjects: 551
Study 23391676 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 551
Study 23391676 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol 300 mg daily
Number of subjects: 551
Study 21184110 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic suturing
Number of subjects: 117
Study 21184110 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic suturing
Number of subjects: 117
Study 21184110 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for suturing method
Number of subjects: 117
Study 19470936 — intervention group
Group type: EXPERIMENTAL
Intervention: MDM2 overexpression
Number of subjects: 478
Study 19470936 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 overexpression
Number of subjects: 478
Study 19470936 — intervention group
Group type: EXPERIMENTAL
Intervention: P53 overexpression
Number of subjects: 478
Study 19470936 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined overexpression of Ki-67 and MDM2
Number of subjects: 478
Study 17094002 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted cervical pedicle screw insertion (Navigation group)
Number of subjects: 27
Study 17094002 — intervention group
Group type: COMPARATOR
Intervention: Conventional cervical pedicle screw insertion (Conventional group)
Number of subjects: 27
Study 16422960 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil 10 mg or 20 mg
Number of subjects: 1385
Study 16422960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1385
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in pregnancy/perinatal medicine
Number of subjects: 2000
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions in myocardial infarction
Number of subjects: 2000
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium in myocardial infarction
Number of subjects: 2000
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium for prevention of pre-eclampsia
Number of subjects: 2000
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet agents for prevention of pre-eclampsia
Number of subjects: 2000
Study 11158556 — intervention group
Group type: EXPERIMENTAL
Intervention: Other unspecified interventions
Number of subjects: 2000
Study 9732932 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 118
Study 9732932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 7994946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral total knee arthroplasty with femoral canal decompression using an overdrilled entrance hole and fluted guide rod
Number of subjects: 35
Study 7994946 — intervention group
Group type: COMPARATOR
Intervention: Unilateral total knee arthroplasty
Number of subjects: 35
Study 2525996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis)
Number of subjects: 82
Study 2525996 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg BID)
Number of subjects: 82
Study 2525996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (for pyelonephritis)
Number of subjects: 82
Study 2525996 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (for pyelonephritis)
Number of subjects: 82
Study 2525996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (for cystitis)
Number of subjects: 82
Study 2525996 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (for cystitis)
Number of subjects: 82
Study 26983904 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 133
Study 26983904 — intervention group
Group type: COMPARATOR
Intervention: Child-Centered Therapy (CCT)
Number of subjects: 133
Study 28753932 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng (3000 mg/day) for three months
Number of subjects: 30
Study 28753932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 25467231 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 30
Study 25467231 — intervention group
Group type: COMPARATOR
Intervention: CH
Number of subjects: 30
Study 23979005 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight gain prevention intervention (medium-intensity) including tailored behavior change goals, weekly self-monitoring via interactive voice response, monthly counseling calls, tailored skills training materials, and a gym membership.
Number of subjects: 194
Study 23979005 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 194
Study 23979005 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight gain prevention intervention (medium-intensity)
Number of subjects: 194
Study 21782874 — intervention group
Group type: EXPERIMENTAL
Intervention: rHPIV3cp45 vaccine (10^5 TCID50 dose)
Number of subjects: 30
Study 21782874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19035501 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,000 mg of calcium and 400 IU of vitamin D)
Number of subjects: 198
Study 19035501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (with 400 IU of vitamin D)
Number of subjects: 198
Study 16798389 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and aspirin plus bivalirudin
Number of subjects: 15222
Study 16798389 — intervention group
Group type: COMPARATOR
Intervention: No initial Q waves
Number of subjects: 15222
Study 12672184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (low dose 0.05 mg/kg, maximum 5 mg)
Number of subjects: 0
Study 12672184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (mid-dose 0.2 mg/kg, maximum 20 mg)
Number of subjects: 0
Study 12672184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 45‐2081 (high dose 0.5 mg/kg, maximum 50 mg)
Number of subjects: 0
Study 12672184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9658758 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (20 MHz) ultrasound probe (HFUP)
Number of subjects: 27
Study 8704438 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxueshengru Oral Liquor (YXSR)
Number of subjects: 103
Study 2666884 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 2 g cefotetan
Number of subjects: 75
Study 2666884 — intervention group
Group type: COMPARATOR
Intervention: Triple dose of 1 g intravenous cephazolin
Number of subjects: 75
Study 338399 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (Ludiomil)
Number of subjects: 75
Study 338399 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 75
Study 30457349 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 160
Study 30457349 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine
Number of subjects: 160
Study 28724846 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg three times daily for nine months)
Number of subjects: 76
Study 28724846 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 or 15 mg once daily for nine months)
Number of subjects: 76
Study 28724846 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Orlistat and Sibutramine
Number of subjects: 76
Study 24300630 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential treatment
Number of subjects: 71
Study 24300630 — intervention group
Group type: COMPARATOR
Intervention: 10-day conventional treatment
Number of subjects: 71
Study 21786524 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 74
Study 21786524 — intervention group
Group type: COMPARATOR
Intervention: 75 mg pregabalin
Number of subjects: 74